



## **Haleon plc: Proposed off-market purchase alongside Pfizer Inc. offering**

**18 March 2025:** Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) notes the announcement today by Pfizer Inc. ("Pfizer") of its proposed offering of ordinary shares of £0.01 each in the Company to institutional investors by way of an accelerated bookbuild offering process (the "Proposed Offering").

Haleon has agreed with Pfizer to make an off-market purchase of approximately £170 million worth of ordinary shares from Pfizer, subject to (a) the offering price per ordinary share in the Proposed Offering (the "Share Offering Price") being no more than the price per ordinary share as at close of trading today on the main market of the London Stock Exchange, and (b) completion of the Proposed Offering.

Subject to completion of the off-market purchase, the purchase price per ordinary share to be paid by Haleon to Pfizer will be equal to the Share Offering Price.

The off-market purchase will represent a portion of the £500 million allocated to share buybacks in 2025 announced on 27 February 2025. Haleon intends to cancel the purchased ordinary shares.

Further details will be provided following announcement by Pfizer of the results of the Proposed Offering.

**Amanda Mellor**  
**Company Secretary**

### **Enquiries**

#### **Investors**

Jo Russell                    +44 7787 392441  
Rakesh Patel                +44 7552 484646  
Emma White                +44 7823 523562

Email: [investor-relations@haleon.com](mailto:investor-relations@haleon.com)

#### **Media**

Zoë Bird                    +44 7736 746167  
Victoria Durman            +44 7894 505730

Email: [corporate.media@haleon.com](mailto:corporate.media@haleon.com)

### **About Haleon**

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

For more information please visit [www.haleon.com](http://www.haleon.com)

Not for release, publication or distribution in the United States, Canada, Japan, Australia or any other state or jurisdiction in which such release, publication or distribution would be unlawful.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [ms@seg.com](mailto:ms@seg.com) or visit [www.ms.com](http://www.ms.com).

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

MSCQVLFFEXLZBBV